Company news

Prescient Therapeutics Limited news in 2017

Prescient Therapeutics Limited's news releases, calls and decks from 2017, newest first.

View company

Clinical Hold Lifted on PTX-200 Breast Cancer Trial

December 10, 2017

PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer

November 5, 2017

September 2017 Appendix 4C - Quarterly

October 26, 2017

PTX-100 to Re-enter Trials in Hematology Niche

October 2, 2017

Prescient to resume AML trial

September 3, 2017

Appendix 4E and 2017 Annual Report

August 29, 2017

June 2017 Appendix 4C - Quarterly

July 25, 2017

Novel PTX-100 Cancer Approach Published in Nature

June 18, 2017

Clinical Trial Update

May 28, 2017

PTX Broker Presentation

May 16, 2017

European Patent Granted for PTX-200

May 11, 2017

Kansas University Joins PTXs AML Trial

May 7, 2017

FDA Grants Orphan Drug Designation for PTX-200 in AML

April 30, 2017

March 2017 Appendix 4C - Quarterly

April 27, 2017

Successful Completion of Phase 1b Breast Cancer Trial

April 6, 2017

Three Additional US Patents Granted

March 15, 2017

First Cohort Successfully Completed in Phase 1b/2 AML Trial

March 7, 2017

December 2016 Appendix 4C - Quarterly

January 24, 2017

Decks in 2017